Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.5 - $261.0 $185,651 - $96.9 Million
-371,303 Reduced 76.49%
114,131 $74,000
Q3 2022

Nov 14, 2022

SELL
$1.04 - $322.5 $469,524 - $146 Million
-451,466 Reduced 48.19%
485,434 $835,000
Q2 2022

Aug 12, 2022

BUY
$0.41 - $1.24 $384,129 - $1.16 Million
936,900 New
936,900 $1.16 Million
Q4 2021

Feb 14, 2022

SELL
$1.09 - $1.89 $233,260 - $404,460
-214,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$1.44 - $2.73 $242,208 - $459,186
168,200 Added 367.25%
214,000 $389,000
Q2 2021

Aug 12, 2021

BUY
$2.63 - $3.67 $120,454 - $168,086
45,800 New
45,800 $121,000
Q4 2020

Feb 11, 2021

SELL
$2.09 - $3.09 $35,948 - $53,148
-17,200 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$2.39 - $3.43 $41,108 - $58,996
17,200 New
17,200 $43,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $424M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.